Zacks Investment Research cut shares of Recordati (NASDAQ:RCDTF) from a strong-buy rating to a hold rating in a report published on Wednesday morning.

According to Zacks, “Recordati S.p.A. is a pharmaceutical company. It engaged in the research, development, manufacturing and marketing of pharmaceuticals for rare disease treatments. The company operates primarily in Russia, Turkey, North Africa and United States of America. Recordati S.p.A. is headquartered in Milan, Italy. “

Shares of Recordati (NASDAQ:RCDTF) opened at 41.49 on Wednesday. The firm’s 50 day moving average is $41.49 and its 200 day moving average is $34.45. The stock has a market capitalization of $8.53 billion and a price-to-earnings ratio of 29.81. Recordati has a 52-week low of $23.90 and a 52-week high of $41.49.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Downgrades Recordati (NASDAQ:RCDTF) to Hold” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at

Get a free copy of the Zacks research report on Recordati (RCDTF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Recordati Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati and related companies with Analyst Ratings Network's FREE daily email newsletter.